NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
June 03, 2023 12:15 ET
|
NewAmsterdam Pharma Company B.V.
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, May 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
May 23, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, May 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
May 08, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
-- Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (“HeFH”) ahead of schedule; topline results expected in 2H...
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
April 24, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options ---- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and...
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
April 03, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected...
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
March 01, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, March 01, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
February 09, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
January 17, 2023 08:00 ET
|
NewAmsterdam Pharma Company B.V.
-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) ---- Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm ----...